Abbott Laboratories (ABT)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
As of 09:58AM EDT. Market open.
| Previous close | 106.29 |
| Open | 106.66 |
| Bid | 105.70 x 800 |
| Ask | 105.73 x 800 |
| Day's range | 105.46 - 106.54 |
| 52-week range | 89.67 - 121.64 |
| Volume | |
| Avg. volume | 5,670,939 |
| Market cap | 183.443B |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | 32.93 |
| EPS (TTM) | 3.21 |
| Earnings date | 18 Jul 2024 - 22 Jul 2024 |
| Forward dividend & yield | 2.20 (2.07%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | 126.69 |
ZacksIs Trending Stock Abbott Laboratories (ABT) a Buy Now?
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
© 2024 Yahoo. All rights reserved.